首页 | 官方网站   微博 | 高级检索  
     


Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease
Authors:Sahra Ali  Alexandre Moreau  Daniela Melchiorri  Jorge Camarero  Filip Josephson  Odoardo Olimpier  Jonas Bergh  Dominik Karres  Kyriaki Tzogani  Christian Gisselbrecht  Francesco Pignatti
Affiliation:1. European Medicines Agency, Amsterdam, The Netherlands;2. French National Agency for Medicines and Health Products Safety, Saint-Denis Cedex, France;3. Department of Physiology and Pharmacology, University of Rome, Sapienza, Rome, Italy;4. Spanish Medicines Agency, Madrid, Spain;5. Medical Products Agency, Department of Efficacy and Safety 3, Uppsala, Sweden;6. Italian Medicines Agency, European Assessment Unit, Rome, Italy;7. Department of Oncology-Pathology, Karolinska Institutet, BES, Cancer Theme, Karolinska University Hospital Bioclinicum, Solna, Sweden;8. Hôpital Saint Louis, Institut d'Hématalogie, Paris, France
Abstract:
Keywords:Acute lymphoblastic leukemia  Hematopoietic stem cell transplant  Minimal residual disease  CHMP  PRAC  EMA  COMP
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号